As astrocytomas increase in malignancy, GSH levels rise, potentially due to the downregulation of GLUD1 and GPT2, leading to increased glutamate availability for GSH synthesis [137]. This evidence concerns the gene GPT2 and astrocytoma (excluding glioblastoma).